IL6 and rheumatoid arthritis: Furthermore, the introduction of these medications has broadened the therapeutical approach to RA due to the availability of biosimilar Tumor Necrosis Factor inhibitors (TNFi), target-cells, interleukin-6, or T-cell co-stimulation [32,33].